A Double Blind, Placebo-Controlled, Multi-Centre Study to Evaluate the Efficacy, Safety, Tolerability and Immunogenicity of Repeated s.c Administrations of 100µg NIC002 Vaccine in Cigarette Smokers Who Are Motivated to Quit Smoking.

Trial Profile

A Double Blind, Placebo-Controlled, Multi-Centre Study to Evaluate the Efficacy, Safety, Tolerability and Immunogenicity of Repeated s.c Administrations of 100µg NIC002 Vaccine in Cigarette Smokers Who Are Motivated to Quit Smoking.

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Mar 2017

At a glance

  • Drugs NIC 002 (Primary)
  • Indications Smoking withdrawal; Substance-related disorders
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 Nov 2009 Actual end date (Oct 2009) added as reported by ClinicalTrials.gov.
    • 04 Nov 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 15 Oct 2009 Primary endpoint 'Clinical response' has not been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top